Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Published Online
on July 2, 2007

Hypertension. 2007
Published online before print July 2, 2007, doi: 10.1161/HYPERTENSIONAHA.107.090290
A more recent version of this article appeared on August 1, 2007
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
50/2/299    most recent
HYPERTENSIONAHA.107.090290v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mancia, G.
Right arrow Articles by Pepine, C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mancia, G.
Right arrow Articles by Pepine, C. J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*High Blood Pressure
Hazardous Substances DB
*VERAPAMIL HYDROCHLORIDE
Related Collections
Right arrow Clinical Studies
Right arrowRelated Article

Submitted on March 12, 2007
Revised on April 1, 2007

Blood Pressure Control and Improved Cardiovascular Outcomes in the International Verapamil SR-Trandolapril Study

Giuseppe Mancia*; Franz Messerli; George Bakris; Qian Zhou; Annette Champion; and Carl J. Pepine

From the Clinica Medica (G.M.), Dipartimento di Medicina Clinica, Prevenzione, Università Milano Bicocca, Milan, Italy; Division of Cardiology (F.M.), St Luke’s-Roosevelt Hospital, New York; Pritzker School of Medicine (G.B.), University of Chicago, Ill; Abbott Laboratories (Q.Z., A.C.), Abbott Park, Ill; and the Division of Cardiovascular Medicine (C.J.P.), Department of Medicine, University of Florida, Gainesville.

* To whom correspondence should be addressed. E-mail: giuseppe.mancia{at}unimib.it.

Abstract--Uncontrolled blood pressure (BP) increases cardiovascular risk, independent of type of treatment. In this posthoc International Verapamil SR-Trandolapril Study analysis, we determined whether adverse outcomes are related to consistency of BP control, defined as the proportion of visits in which BP was in control. A total of 22 576 patients with hypertension and coronary artery disease were divided into 4 groups according to the proportion of visits in which BP was in control (<140/90 mm Hg): <25%, 25% to <50%, 50% to <75%, and ≥75%. Risk of primary outcome (first occurrence of death, nonfatal myocardial infarction, or nonfatal stroke), myocardial infarction, and stroke decreased progressively from the group with <25% to the group with ≥75% of visits with BP control. Adjusted risks of primary outcome (heart rate: 0.60; 95% CI: 0.53 to 0.67), myocardial infarction (heart rate: 0.58; 95% CI: 0.48 to 0.70), and stroke (heart rate: 0.50; 95% CI: 0.37 to 0.67) were less in the group with ≥75% of visits with BP control compared with the group with <25% of visits with BP control. Baseline BP was not predictive of outcomes. Proportion of visits with BP control was associated with mean follow-up systolic BP (r2=0.64), both being independently related to primary outcome. As proportion of visits with BP control increases, there is an associated steep reduction in cardiovascular risk, independent of baseline characteristics and mean on-treatment BP. Consistency of BP control during treatment provides additional information on the protective effect of antihypertensive treatment. Physicians need to be concerned at each visit if BP is not controlled.


Key words: hypertension • blood pressure control • antihypertensive treatment • antihypertensive drugs • blood pressure measurement/monitoring • clinical trials


Related Article:

Hypertension Treatment: How Important Is Consistency of Effect?
Domenic A. Sica
Hypertension 2007 50: 287-288. [Full Text] [PDF]



This article has been cited by other articles:


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
B. Gojanovic, F. Feihl, L. Liaudet, and B. Waeber
Review: Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension
Journal of Renin-Angiotensin-Aldosterone System, March 1, 2008; 9(1): 1 - 9.
[Abstract] [PDF]


Home page
HypertensionHome page
D. A. Sica
Hypertension Treatment: How Important Is Consistency of Effect?
Hypertension, August 1, 2007; 50(2): 287 - 288.
[Full Text] [PDF]